Methamphetamine and Troriluzole
ConditionMethamphetamine Use Disorder
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorWilliam Stoops
About this trial
This will be a human laboratory study evaluating the influence of troriluzole treatment on the effects of methamphetamine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
able to speak/read English,
not seeking treatment for drug use at the time of the study,
female or male between the ages of 18 and 55 years,
recent methamphetamine use verified by methamphetamine positive urine, as well as fulfillment of DSM-5 diagnostic criteria for MUD,
Disqualifiers
unable to speak/read English,
seeking treatment for drug use,
under 18 years or over 55 years,
no recent methamphetamine use as indicated by methamphetamine negative urine and no DSM-5 diagnosis of MUD,
Trial design
Design model
Crossover
Treatments tested in this trial
Placebo
DrugThe effects of placebo will be determined.
Methamphetamine
DrugPlacebo and methamphetamine will be administered intravenously during experimental sessions.
Treatment groups
40 Participants
are divided into 3 treatment groupsGroup A: PlaceboPlacebo comparator 1 intervention
Group B: Troriluzole Dose 1Experimental treatment 2 interventions
Group C: Troriluzole Dose 2Experimental treatment 2 interventions
Trial outcomes
Primary outcomes
1
Reinforcing Effects of Methamphetamine
Number of Times Subjects Hypothetically Choose Methamphetamine Over Money between $0 and $140
Time frame
9 times over approximately 1 month inpatient admissionSponsors and contacts
Click on the lead sponsor to view all of their trials.
William Stoops
Lead sponsor
University of Kentucky
Sponsor institution
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov